SCHEMBL6153546

SCHEMBL6153546

Cc1ccc(Nc2nnc(-c3cccc(OCc4ccccc4)c3)s2)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GUSB P08236 2/20 0.49
ROCK1 Q13464 2/20 0.47
ROCK2 O75116 1/20 0.47
DHODH Q02127 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 2/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
NR1H2 P55055 1/20 0.44
MGAM O43451 2/20 0.43
GAA P10253 2/20 0.43
SI P14410 2/20 0.43
MGAM2 Q2M2H8 2/20 0.43
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
MAPT P10636 2/20 0.41
HDAC1 Q13547 4/20 0.41
HDAC2 Q92769 4/20 0.41
HDAC8 Q9BY41 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6677778 0.86 MGAM (0.51) DHODHNR1H2MGAMGAASI
SCHEMBL6690137 0.86 GUSB (0.48) GUSBROCK1ROCK2DHODHMEN1
SCHEMBL6154349 0.82 GUSB (0.60) GUSBROCK1ROCK2DHODHMEN1
SCHEMBL6156436 0.81 GUSB (0.49) GUSBROCK1ROCK2DHODHMEN1
SCHEMBL6154386 0.79 GUSB (0.51) GUSBROCK1ROCK2MEN1KMT2A
SCHEMBL6154672 0.79 GUSB (0.61) GUSBROCK1ROCK2DHODHMEN1
SCHEMBL6684447 0.77 GUSB (0.48) GUSBROCK1ROCK2DHODHMEN1
SCHEMBL6155142 0.76 GUSB (0.60) GUSBROCK1ROCK2DHODHMEN1
SCHEMBL6153921 0.76 NOTUM (0.53) GUSBROCK1ROCK2MEN1KMT2A
SCHEMBL6154585 0.76 NOTUM (0.53) GUSBROCK1ROCK2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2005-03-24 US claimed
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2005-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases PTPRS, PTPRJ, PTPRCAP GUSB 2466/4885ROCK1 3290/4885ROCK2 3224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.